New to Treatment?

Is treatment new for you? There are a variety of factor VIII products available to people living with hemophilia. The wealth of information available can be both overwhelming and confusing. To help you, with your healthcare provider, decide which product treatment is the best option for you, learn more about how the factor VIII product options compare to each other in this convenient, product comparison chart.

The resources provided here can provide critical information and support to assist you and your family with your treatment needs and questions. Our Hematology Account Executives also are an excellent resource for addressing clinical challenges in hemophilia A and optimizing your Kogenate^® FS, Antihemophilic Factor (Recombinant) treatment. Contact your Hematology Account Executive today to find out more about Kogenate FS with BIO-SET^® and the resources available to you and your family.

Your Hemophilia Treatment Center can provide specialty treatment with the goal of minimizing complications from bleeding episodes.

Interested in a Kogenate FS with BIO-SET free trial? Patients with hemophilia A can now experience the benefits of Kogenate FS with BIO-SET Factor VIII therapy for free.

INDICATIONS & USAGE

Kogenate® FS, antihemophilic factor (recombinant), is a recombinant factor VIII treatment indicated for the control and prevention of bleeding episodes and peri-operative management in adults and children (0-16 years) with hemophilia A. Kogenate® FS is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A with no preexisting joint damage.

IMPORTANT SAFETY INFORMATION

The most serious adverse reactions are systemic hypersensitivity reactions and the development of hightiter inhibitors necessitating alternative treatments to AHF. The most common adverse reactions observed in clinical trials were inhibitor formation in previously untreated or minimally treated patients, skin-associated hypersensitivity reactions, infusion site reactions, and central venous access device (CVAD) line-associated infections.

Kogenate® FS is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including mouse or hamster proteins.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

For important risk and use information, please see the full prescribing information.

Prescribing Information | Privacy Policy | Terms of Use | Sitemap

© 2010 Bayer HealthCare Pharmaceuticals, Inc. All rights reserved.
BAYER, the Bayer Cross, and Kogenate FS are registered trademarks of Bayer HealthCare Pharmaceuticals.
BIO-SET is a trademark of Biodome SAS.

Kogenate FS Antihemophilic Factor (Recombinant) with BIO-SET Needleless Reconstitution System

Bayer HealthCare Pharmaceuticals